首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1560843

全球寡核苷酸合成市場 - 2024 - 2031

Global Oligonucleotide Synthesis Market - 2024 - 2031

出版日期: 2024年09月23日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

2023年全球寡核苷酸合成市場規模達75億美元，預計2031年將達152億美元，2024-2031年預測期間複合年成長率為9.0%

寡核苷酸合成是產生短核苷酸序列（稱為寡核苷酸）的化學程序，用於分子生物學、生物技術和治療應用。這些合成的 DNA 或 RNA 鏈用於遺傳分析、診斷和治療。這項技術的進步帶來了個人化醫療、基於 RNA 的疫苗和遺傳疾病的標靶治療。由於基因組學、生物製藥和診斷學的創新，合成寡核苷酸市場持續擴大。

市場動態：

驅動程式和限制

增加對製藥和生技公司的投資

寡核苷酸合成市場受到政府資金和研究的大量投資的推動，促進了創新和治療探索。然而，成本侵蝕和缺乏標準化指南等挑戰構成了潛在的障礙。因此，利害關係人必須駕馭這些市場動態，以在不久的將來充分利用市場的成長潛力。

例如，2024 年6 月，GSK plc 宣布以高達5,000 萬美元（約3,900 萬英鎊）的價格收購了Elsie Biotechnologies，這是一家總部位於聖地亞哥的私人生物技術公司，致力於釋放寡核苷酸療法的全部潛力。寡核苷酸具有調節基因表現的獨特能力，使其成為解決大部分傳統小分子或生物製劑無法解決的治療標靶的一種有吸引力的方式。

成本侵蝕

由於成本侵蝕、治療性寡核苷酸指南的不確定性以及缺乏統一指南，寡核苷酸合成市場面臨挑戰。這些因素可能會影響利潤率和市場永續性，阻礙寡核苷酸合成技術的無縫發展。對於產業利害關係人來說，有效應對這些挑戰對於分子診斷和臨床應用的持續成長至關重要。

細分市場分析

全球寡核苷酸合成市場根據產品類型、應用、最終用戶和地區進行細分。

該產品類型細分市場的試劑約佔寡核苷酸合成市場佔有率的41.3%

產品類型細分市場的試劑佔比約41.3%。全球寡核苷酸合成市場嚴重依賴試劑，包括亞磷醯胺、溶劑、催化劑和封端劑，它們控制合成過程的效率、準確性和產量。高品質試劑可確保寡核苷酸鏈的保真度並最大限度地減少錯誤。由於基因編輯、診斷和治療領域對精確可靠的寡核苷酸的需求不斷成長，合成試劑市場已顯著擴大。基於寡核苷酸的研究的成功和新型療法的開發與試劑品質的進步直接相關。

例如，2024年9月，Emp Biotech與Atom Scientific合作，在英國和愛爾蘭分銷其高品質寡核苷酸合成試劑，標誌著該公司寡核苷酸合成產品的獨家分銷合作夥伴關係。

市場地域佔有率

預計北美在整個預測期內將佔據總市場佔有率的 38.4% 左右

由於生命科學和醫療保健領域的研發投資不斷增加，以及對開發各種疾病的個人化療法的日益關注，北美預計將在整個預測期內佔據總市場佔有率的38.4% 左右，這是支撐該市場巨大佔有率的主要因素。

例如，2024 年 5 月，領先的酶工程公司 Codexis, Inc. 宣布，它透過酶途徑成功合成了寡核苷酸，以支持基於 RNA 的治療藥物的生產。 Codexis 首次透過連接綴合部分從起始材料酵素合成全長寡核苷酸，為 RNAi 治療產業的替代製造方法提供了重要的製程證明。

此外，美國癌症協會預測，到2024年，美國將有2,001,140例新癌症病例和611,720例癌症相關死亡。成長。合成寡核苷酸用於各種研究和診斷應用。

Oligonucleotide synthesis is the chemical process of creating short nucleotide sequences, known as oligonucleotides, for molecular biology, biotechnology, and therapeutic applications. These synthetic DNA or RNA strands are used in genetic analysis, diagnostics, and therapeutics. Advancements in this technology have led to personalized medicine, RNA-based vaccines, and targeted therapies for genetic diseases. The market for synthetic oligonucleotides continues to expand due to innovations in genomics, biopharmaceuticals, and diagnostics.

Market Dynamics: Drivers & Restraints

Increased investment in pharmaceutical and biotechnology companies

The oligonucleotide synthesis market is boosted by substantial investment from government funds and research, promoting innovation and therapeutic exploration. However, challenges like cost erosion and lack of standardized guidelines pose potential hindrances. Therefore, stakeholders must navigate these market dynamics to fully capitalize on the market's growth potential in the near future.

For instance, in June 2024, GSK plc announced that it had acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million). Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.

Erosion of costs

The oligonucleotide synthesis market faces challenges due to cost erosion, uncertainty in therapeutic oligo guidelines, and a lack of unified guidelines. These factors could impact profit margins and market sustainability, hindering the seamless progression of oligonucleotide synthesis technologies. It is crucial for industry stakeholders to effectively address these challenges for sustained growth in molecular diagnostics and clinical applications.

Market Segment Analysis

The global oligonucleotide synthesis market is segmented based on product type, application, end-user, and region.

The reagents from the product type segment accounted for approximately 41.3% of the oligonucleotide synthesis market share

The reagents from the product type segment accounted for approximately 41.3%. The global oligonucleotide synthesis market relies heavily on reagents, including phosphoramidites, solvents, catalysts, and capping agents, which control the efficiency, accuracy, and yield of the synthesis process. High-quality reagents ensure the fidelity of oligonucleotide chains and minimize errors. The market for synthesis reagents has expanded significantly due to the growing demand for precise and reliable oligonucleotides in gene editing, diagnostics, and therapeutics. The success of oligonucleotide-based research and the development of novel therapeutics are directly linked to reagent quality advancements.

For instance, in September 2024, Emp Biotech partnered with Atom Scientific to distribute its high-quality oligonucleotide synthesis reagents in the UK and Ireland, marking an exclusive distribution partnership for the company's oligonucleotide synthesis products.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increasing R&D investments in the field of life sciences and healthcare and the growing focus on developing personalized therapeutics for various diseases are major factors supporting the large share of this market.

For instance, in May 2024, Codexis, Inc. a leading enzyme engineering company, announced it successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Codexis has achieved the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety, providing a significant proof of process for alternative manufacturing methods in the RNAi therapeutics industry.

Moreover, the American Cancer Society predicts that in the year 2024, there will be 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S. As the demand for new and improved cancer treatments increases, the requirement for synthetic oligonucleotides is growing. The synthetic oligonucleotides are used in a variety of research and diagnostic applications.

Market Segmentation

By Product Type

Reagents

Equipment

Synthesized Oligonucleotides

Oligonucleotide-based drugs

Primers

Probes

Large-scale synthesized oligonucleotides

Others

By Application

Research

PCR

QPCR

Sequencing

Gene Synthesis

Others

Diagnostics

Therapeutics

DNA & Oligonucleotide-based therapies

RNAi Oligonucleotide-based therapies

CpG Oligonucleotide-based therapies

By End User

Hospitals

Academic & Research Institutes

Pharmaceutical & Biotechnology companies

Diagnostic Laboratories

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Thermo Fisher Scientific Inc., Agilent Technologies Inc., Integrated DNA Technologies (IDT), LGC Biosearch Technologies, Bio-Synthesis Inc., GE Healthcare (Cytiva), Eurofins Genomics, TriLink BioTechnologies (a Maravai LifeSciences company), Merck KGaA (Sigma-Aldrich), ATDBio Ltd among others.

Key Developments

In May 2024, Molecular Assemblies, Inc. a pioneer and leader in the field of enzymatic DNA synthesis, announced the launch of its Partnering Program to license Molecular Assemblies' Fully Enzymatic SynthesisTM (FESTM) technology for onsite synthesis. FES technology accelerates the production of long, pure, and accurate DNA to power a new rapidly emerging generation of therapeutics and diagnostics.

In March 2023, Ansa successfully synthesized a 1005-base-long oligonucleotide with industry-leading accuracy, marking a significant advancement in oligonucleotide synthesis. The company launched an Early Access Program for clonal synthetic genes in April 2023 to assist researchers in obtaining challenging sequences, such as the 1005 base sequence for gene therapy development, which is highly complex and requires the assembly of shorter oligonucleotides.

Why Purchase the Report?

To visualize the global oligonucleotide synthesis market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the oligonucleotide synthesis market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global oligonucleotide synthesis market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increased investment in pharmaceutical and biotechnology companies
  - 4.1.1.2. Advancements in the research and development
- 4.1.2. Restraints
  - 4.1.2.1. Erosion of costs
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Reagents*
- 6.2.1. Introduction
6.3. Equipment
6.4. Synthesized Oligonucleotides

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.2. Market Attractiveness Index, By Application
7.3. Research*
- 7.3.1. Introduction
- 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Diagnostics
7.5. Therapeutics

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Academic & Research Institutes
8.4. Pharmaceutical & Biotechnology companies
8.5. Diagnostic Laboratories

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. UK
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Thermo Fisher Scientific Inc*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Agilent Technologies Inc.
11.3. Integrated DNA Technologies (IDT)
11.4. LGC Biosearch Technologies
11.5. Bio-Synthesis Inc.
11.6. GE Healthcare (Cytiva)
11.7. Eurofins Genomics
11.8. TriLink BioTechnologies (a Maravai LifeSciences company)
11.9. Merck KGaA (Sigma-Aldrich)
11.10. ATDBio Ltd. (*LIST NOT EXHAUSTIVE)